Research Institute of Dallas | Dallas, TX
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this trial is to assess the long-term safety and efficacy of CAM2029 in patients with acromegaly. Patients will be administered CAM2029 subcutaneously once monthly during 12 months. Patients fulfilling trial NCT04076462 will be offered to continue with open-label treatment week 24-52 in this trial. Patients completing the main part of the trial will be offered 52 weeks continued open-label treatment in an extension part.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
For Roll-over Patients from NCT04076462:
For New Patients:
Primary purpose
Allocation
Interventional model
Masking
135 participants in 1 patient group
Loading...
Central trial contact
Camurus AB
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal